We are live on ! Find out more
VanEck Associates

VanEck Associates Portfolio holdings

AUM $133B
1-Year Est. Return 72.99%
This Fund
S&P 500
This Quarter Est. Return
+10.98%
1 Year Est. Return
+72.99%
3 Year Est. Return
+157.94%
5 Year Est. Return
+206.35%
10 Year Est. Return
+770.56%
AUM
$21.7B
AUM Growth
+$1.52B
Cap. Flow
-$396M
Cap. Flow %
-1.83%
Top 10 Hldgs %
30.74%
Holding
733
New
39
Increased
433
Reduced
235
Closed
15

Top Sells

Rank Stock Value
1
MON
Monsanto Co
MON
+$84.2M
2
SYT
Syngenta Ag
SYT
+$72.8M
3
NOV icon
NOV
NOV
+$66.8M
4
DE icon
Deere & Co
DE
+$66.6M
5
POT
Potash Corp Of Saskatchewan
POT
+$66.4M

Sector Composition

Rank Sector Weight
1 Materials 45.09%
2 Energy 26.66%
3 Healthcare 4.74%
4 Industrials 3.46%
5 Consumer Staples 2.43%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
GLNG icon
126
Golar LNG
GLNG
$4.95B
$30.6M 0.14%
+509,000
New +$23.9M
AGCO icon
127
AGCO
AGCO
$8.78B
$30M 0.14%
533,997
-225,015
-30% -$12.4M
VRTX icon
128
Vertex Pharmaceuticals
VRTX
$121B
$28.5M 0.13%
301,319
-59,317
-16% -$4.16M
GORO icon
129
Goldgroup Mining Inc.
GORO
$151M
$27.7M 0.13%
5,471,540
+1,525,911
+39% +$6.97M
TRX icon
130
TRX Gold Corp
TRX
$255M
$27.6M 0.13%
12,196,643
+1,394,436
+13% +$2.98M
STNG icon
131
Scorpio Tankers
STNG
$3.96B
$27.2M 0.13%
267,530
+4,540
+2% +$414K
ANV
132
DELISTED
Allied Nevada Gold Corp
ANV
$26.7M 0.12%
7,109,693
-1,605,552
-18% -$5.57M
PFE icon
133
Pfizer
PFE
$140B
$25.3M 0.12%
896,699
+137,531
+18% +$3.92M
ALXN
134
DELISTED
Alexion Pharmaceuticals
ALXN
$23.1M 0.11%
148,107
-31,533
-18% -$4.98M
IWO icon
135
iShares Russell 2000 Growth ETF
IWO
$14.5B
$22.7M 0.1%
164,111
-144,370
-47% -$19M
PTEN icon
136
Patterson-UTI
PTEN
$3.87B
$22.6M 0.1%
645,469
+8,140
+1% +$267K
ILMN icon
137
Illumina
ILMN
$29.4B
$22.5M 0.1%
129,350
-45,519
-26% -$6.79M
TTC icon
138
Toro Company
TTC
$8.93B
$22.5M 0.1%
706,178
-210,074
-23% -$6.7M
IDXX icon
139
Idexx Laboratories
IDXX
$42.9B
$21.4M 0.1%
321,184
-97,984
-23% -$6.23M
GPL
140
DELISTED
Great Panther Mining Limited
GPL
$21.4M 0.1%
1,695,851
+195,521
+13% +$2.06M
NLY icon
141
Annaly Capital Management
NLY
$16.9B
$20.7M 0.1%
452,570
+61,732
+16% +$2.85M
ASML icon
142
ASML
ASML
$675B
$20.3M 0.09%
218,009
+36,008
+20% +$3.11M
REGN icon
143
Regeneron Pharmaceuticals
REGN
$68.8B
$20.3M 0.09%
71,950
-22,314
-24% -$6.61M
MU icon
144
Micron Technology
MU
$1.04T
$20.3M 0.09%
616,478
-49,857
-7% -$1.36M
DNOW icon
145
DNOW Inc
DNOW
$2.63B
$19.8M 0.09%
+546,041
New +$18.8M
MRK icon
146
Merck
MRK
$324B
$19.7M 0.09%
356,842
+53,477
+18% +$2.92M
INCY icon
147
Incyte
INCY
$23.5B
$19.5M 0.09%
345,911
-56,615
-14% -$2.89M
QGENF
148
DELISTED
QIAGEN NV
QGENF
$19.5M 0.09%
798,452
-145,663
-15% -$3.56M
RDC
149
DELISTED
Rowan Companies Plc
RDC
$19.2M 0.09%
601,826
+7,972
+1% +$250K
MDW
150
DELISTED
MIDWAY GOLD CORP (CANADA)
MDW
$19.2M 0.09%
21,292,475
+3,085,022
+17% +$2.69M

Similar funds

VanEck Associates's Q2 2014 Portfolio in Review

As of Q2 2014, VanEck Associates held 733 positions worth $21.7B, up 7.6% from $20.1B the previous quarter. Its ten largest holdings account for 31% of the portfolio.

VanEck Associates's Q2 2014 filing shows 39 new, 433 increased, 235 reduced and 15 closed positions. Its largest new stake was MAG Silver: 5,536,686 shares worth $52.4M. The largest sale was Monsanto Co, an estimated $84.2M.

By sector, the portfolio is most concentrated in Materials at 45% of assets, up from 45% a quarter earlier, followed by Energy and Healthcare.

  • VanEck Associates's largest Q2 2014 buy was MAG Silver: 5,536,686 shares worth $52.4M.
  • VanEck Associates added most to Yamana Gold, Inc. in Q2 2014, an estimated $110M increase.
  • VanEck Associates's biggest Q2 2014 reduction was Monsanto Co, cutting an estimated $84.2M.
  • VanEck Associates fully exited Weatherford International plc in Q2 2014, selling an estimated $45.6M.
  • VanEck Associates's ten largest holdings make up 31% of its $21.7B portfolio in Q2 2014.
  • VanEck Associates opened 39 new positions and closed 15 in Q2 2014.
  • VanEck Associates's portfolio value rose 7.6% quarter-over-quarter to $21.7B.

Based on VanEck Associates's 13F filing for Q2 2014, filed 14 Aug 2014.